The CONSORT 2010 statement provides minimum guidelines for reporting randomised trials.
Its widespread use has been instrumental in ensuring transparency in the evaluation of …

The SPIRIT 2013 statement aims to improve the completeness of clinical trial protocol
reporting by providing evidence-based recommendations for the minimum set of items to be …

… c–e | The prior and posterior distributions for β intercept (part c), the linear effect of age (years),
β age (part d) and \({\beta }_{{{\rm{age}}}^{2}}\) (part e) are shown. For each chain, the first …

We performed an extensive immunogenomic analysis of more than 10,000 tumors comprising
33 diverse cancer types by utilizing data compiled by TCGA. Across cancer types, we …

For a decade, The Cancer Genome Atlas (TCGA) program collected clinicopathologic
annotation data along with multi-platform molecular profiles of more than 11,000 human tumors …

Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and
cell growth are common hallmarks of cancer, but the extent, mechanisms, and co-…

Gene fusions represent an important class of somatic alterations in cancer. We systematically
investigated fusions in 9,624 tumors across 33 cancer types using multiple fusion calling …

Identifying molecular cancer drivers is critical for precision oncology. Multiple advanced
algorithms to identify drivers now exist, but systematic attempts to combine and optimize them on …

We conducted comprehensive integrative molecular analyses of the complete set of tumors
in The Cancer Genome Atlas (TCGA), consisting of approximately 10,000 specimens and …

Invasive lobular carcinoma (ILC) is the second most prevalent histologic subtype of invasive
breast cancer. Here, we comprehensively profiled 817 breast tumors, including 127 ILC, …